0.78
-0.0479(-5.78%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.81 |
| Day High | 0.85 |
| Day Low | 0.76 |
| 52-Week High | 19.51 |
| 52-Week Low | 0.51 |
| Volume | 100,885 |
| Average Volume | 108,460 |
| Market Cap | 25.83M |
| PE | -7.09 |
| EPS | -0.11 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 2.85 |
| Change | -0.05 |
If you invested $1000 in JUPITER NEUROSCIENCES, INC. (JUNS) since IPO date, it would be worth $0 as of June 07, 2025 at a share price of $0.78. Whereas If you bought $1000 worth of JUPITER NEUROSCIENCES, INC. (JUNS) shares 0 years ago, it would be worth $142.15 as of June 07, 2025 at a share price of $0.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure J
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
GlobeNewswire Inc.
Mar 04, 2025 1:00 PM GMT
First three consumer products expected to launch in Q3 2025, providing near-term revenue growth Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceu
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
GlobeNewswire Inc.
Feb 04, 2025 2:25 PM GMT
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement